Insulin glulisine

Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[4] It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004;[5] it is sold under the trade name Apidra.[6] When injected subcutaneously, it appears in the blood earlier than human insulin.[7] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[8] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[2]

Insulin glulisine
PDB: 6gv0​
Clinical data
Trade namesApidra, Apidra SoloStar
AHFS/Drugs.comMonograph
MedlinePlusa607033
License data
Pregnancy
category
Routes of
administration		Subcutaneous, intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only [2]
  • EU: Rx-only [3]
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC258H384N64O78S6
Molar mass5822.64 g·mol−1
 NY (what is this?)  (verify)

The most common side effects include hypoglycaemia (low blood glucose levels).[3]

Medical uses

Insulin glulisine is indicated for the treatment of diabetes mellitus.[3][2]

References
  1. "Insulin glulisine Use During Pregnancy". Drugs.com. 6 April 2020. Retrieved 21 September 2020.
  2. "Apidra- insulin glulisine injection, solution Apidra SoloStar- insulin glulisine injection, solution". DailyMed. 6 December 2019. Retrieved 21 September 2020.
  3. "Apidra EPAR". European Medicines Agency (EMA). Retrieved 7 October 2020.
  4. "Apidra (insulin glulisine) injection, solution". DailyMed.
  5. "Apidra FDA Approval History". Drugs.com. Retrieved 25 August 2022.
  6. Jasek W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
  7. Garnock-Jones KP, Plosker GL (May 2009). "Insulin glulisine: a review of its use in the management of diabetes mellitus". Drugs. 69 (8): 1035–57. doi:10.2165/00003495-200969080-00006. PMID 19496630. S2CID 41839395.
  8. "Insulin Glulisine". Drugs.com.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.